BrightGene Historical Cash Flow
| 688166 Stock | 30.92 1.21 4.07% |
Analysis of BrightGene Bio cash flow over time is an excellent tool to project BrightGene Bio Medical future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Borrowings of 1.4 B or Other Cashflows From Financing Activities of 88.1 M as it is a great indicator of BrightGene Bio ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining BrightGene Bio Medical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BrightGene Bio Medical is a good buy for the upcoming year.
BrightGene |
About BrightGene Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in BrightGene balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which BrightGene's non-liquid assets can be easily converted into cash.
BrightGene Bio Cash Flow Chart
Add Fundamental
Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Capital Expenditures
Capital Expenditures are funds used by BrightGene Bio Medical to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of BrightGene Bio operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in BrightGene Bio Medical financial statement analysis. It represents the amount of money remaining after all of BrightGene Bio Medical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from BrightGene Bio's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into BrightGene Bio Medical current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrightGene Bio Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At present, BrightGene Bio's Net Borrowings is projected to increase significantly based on the last few years of reporting. The current year's Other Cashflows From Financing Activities is expected to grow to about 88.1 M, whereas Change To Inventory is projected to grow to (73.3 M).
| 2022 | 2023 | 2024 | 2025 (projected) | Dividends Paid | 100.1M | 113.8M | 130.8M | 137.4M | Depreciation | 49.9M | 78.1M | 89.8M | 94.3M |
BrightGene Bio cash flow statement Correlations
Click cells to compare fundamentals
BrightGene Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BrightGene Bio cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (75.7M) | (6.3M) | (94.9M) | (85.8M) | (77.2M) | (73.3M) | |
| Investments | (218.5M) | 8.6M | (153.4M) | (445.2M) | (400.7M) | (380.6M) | |
| Change In Cash | (213.8M) | (6.3M) | 818.5M | 312.5M | 359.3M | 196.5M | |
| Total Cashflows From Investing Activities | (156.0M) | (541.9M) | (889.8M) | (871.6M) | (784.4M) | (745.2M) | |
| Other Cashflows From Financing Activities | (225.0K) | 1.3M | 86.7M | 73M | 84.0M | 88.1M | |
| Depreciation | 30.2M | 41.5M | 49.9M | 78.1M | 89.8M | 94.3M | |
| Capital Expenditures | 355.3M | 909.7M | 726.7M | 389.3M | 447.7M | 371.7M | |
| Total Cash From Operating Activities | 155.4M | 176.1M | 311.3M | 194.8M | 224.0M | 141.4M | |
| Change To Operating Activities | (11.6M) | 11.6M | 4.2M | (21.3M) | (19.2M) | (18.2M) | |
| Net Income | 170.1M | 243.7M | 239.6M | 200.6M | 230.7M | 151.4M | |
| End Period Cash Flow | 339.5M | 333.2M | 1.2B | 940.0M | 1.1B | 1.1B | |
| Other Cashflows From Investing Activities | (477.3K) | 31.8M | 18.6M | 18.2M | 21.0M | 11.2M | |
| Change To Netincome | 6.9M | 17.6M | 8.6M | (4.8M) | (5.5M) | (5.2M) | |
| Change To Liabilities | 8.5M | 43.3M | 115.2M | 126.1M | 145.0M | 152.3M | |
| Free Cash Flow | (199.8M) | (733.6M) | (415.5M) | (185.1M) | (166.6M) | (174.9M) | |
| Change In Working Capital | (78.9M) | (133.0M) | 36.1M | (145.6M) | (131.0M) | (124.5M) | |
| Begin Period Cash Flow | 553.3M | 339.5M | 333.2M | 633.4M | 728.4M | 764.8M | |
| Other Non Cash Items | 22.1M | 12.3M | (3.2M) | 54.0M | 62.1M | 65.2M | |
| Change To Account Receivables | (47.0M) | (50.5M) | (241.9M) | 5.0M | 4.5M | 4.7M | |
| Total Cash From Financing Activities | 439.8M | 185.7M | 703.7M | 1.4B | 1.6B | 1.6B |
Currently Active Assets on Macroaxis
Other Information on Investing in BrightGene Stock
The Cash Flow Statement is a financial statement that shows how changes in BrightGene balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which BrightGene's non-liquid assets can be easily converted into cash.